INCREASED TNF-ALPHA SECRETION BY ALVEOLAR MACROPHAGES FROM PATIENTS WITH RHEUMATOID-ARTHRITIS

被引:39
作者
GOSSET, P
PEREZ, T
LASSALLE, P
DUQUESNOY, B
FARRE, JM
TONNEL, AB
CAPRON, A
机构
[1] HOP CHARITE LILLE,CTR ANDRE VERHAEGHE,RHUMATOL CLIN,LILLE,FRANCE
[2] CHR LILLE,HOP CALMETTE,DEPT PNEUMOL,F-59037 LILLE,FRANCE
来源
AMERICAN REVIEW OF RESPIRATORY DISEASE | 1991年 / 143卷 / 03期
关键词
D O I
10.1164/ajrccm/143.3.593
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Tumor necrosis factor alpha (TNF) and interleukin-1 (IL-1) production by alveolar macrophages (AM) was evaluated in 17 rheumatoid arthritis (RA) patients without interstitial lung disease (ILD, Group 1) and 14 RA patients with clinical ILD (Group 2) in comparison with 10 control subjects. AM after recovery by bronchoalveolar lavage were selected by adherence, and then supernatants were collected after 3 or 24 h of culture. Results showed no modification of IL-1 synthesis in either group of RA patients. Spontaneous TNF production was significantly increased in Group 2 (2.5 +/- 0.5 ng/ml) as well as in Group 1 (2.4 +/- 0.4 ng/ml) compared with control subjects (0.43 +/- 0.1 ng/ml, p < 0.001). In addition, AM from patients untreated or treated exclusively by nonsteroidal antiinflammatory drugs produced similar levels of TNF, whereas those receiving corticosteroids, second-line drugs (such as sulfasalazine, aurothiomalate, and methotrexate), or the combination of both therapy regimens released significantly less TNF. Interestingly, TNF was not different in both groups, but Group 2 had a markedly increased ratio of local immune complex to albumin in bronchoalveolar lavage fluid (0.47 +/- 0.12 versus 0.07 +/- 0.02 in Group 1; p < 0.002). TNF thus appears an additional component of RA subclinical alveolitis in RA, but its prognostic value and its precise role in lung damage remain to be determined. Development of ILD requires certainly complex interactions of synergistic factors, possibly including local immune complexes detected in BAL fluids.
引用
收藏
页码:593 / 597
页数:5
相关论文
共 36 条
[1]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[2]  
BACHWICH PR, 1986, AM J PATHOL, V125, P421
[3]  
BEUTLER B, 1987, NEW ENGL J MED, V316, P379
[4]   MODULATION OF ALVEOLAR MACROPHAGE DRIVEN FIBROBLAST PROLIFERATION BY ALTERNATIVE MACROPHAGE MEDIATORS [J].
BITTERMAN, PB ;
WEWERS, MD ;
RENNARD, SI ;
ADELBERG, S ;
CRYSTAL, RG .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (03) :700-708
[5]  
BUCHAN G, 1988, CLIN EXP IMMUNOL, V73, P449
[6]   PULMONARY INVOLVEMENT IN RHEUMATOID-ARTHRITIS [J].
CERVANTESPEREZ, P ;
TOROPEREZ, AH ;
RODRIGUEZJURADO, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1980, 243 (17) :1715-1719
[7]  
DANIELE RP, 1981, AM REV RESPIR DIS, V124, P738
[8]  
DEBS RJ, 1988, J IMMUNOL, V140, P3482
[9]   IMMUNOFLUORESCENT AND IMMUNOLOGICAL STUDIES OF RHEUMATOID LUNG [J].
DEHORATIUS, RJ ;
WILLIAMS, RC ;
ABRUZZO, JL .
ARCHIVES OF INTERNAL MEDICINE, 1972, 129 (03) :441-+
[10]  
EASTGATE JA, 1988, LANCET, V2, P706